NO320403B1 - Farmasoytisksuspensjonsformulering av formoterol egnet for aerosoladministrering, aerosolleverende anordning og fremgangsmate til fremstilling av aerosolformulering - Google Patents
Farmasoytisksuspensjonsformulering av formoterol egnet for aerosoladministrering, aerosolleverende anordning og fremgangsmate til fremstilling av aerosolformulering Download PDFInfo
- Publication number
- NO320403B1 NO320403B1 NO19985720A NO985720A NO320403B1 NO 320403 B1 NO320403 B1 NO 320403B1 NO 19985720 A NO19985720 A NO 19985720A NO 985720 A NO985720 A NO 985720A NO 320403 B1 NO320403 B1 NO 320403B1
- Authority
- NO
- Norway
- Prior art keywords
- hfa
- formulation
- stated
- aerosol
- ethanol
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 121
- 238000009472 formulation Methods 0.000 title claims description 98
- 239000000443 aerosol Substances 0.000 title claims description 45
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 title claims description 7
- 229960002848 formoterol Drugs 0.000 title claims description 7
- 238000000034 method Methods 0.000 title claims description 4
- 238000012384 transportation and delivery Methods 0.000 title claims description 4
- 239000000725 suspension Substances 0.000 title description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 74
- 239000003380 propellant Substances 0.000 claims description 39
- 229940079593 drug Drugs 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 36
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims description 31
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 claims description 27
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims description 27
- 229960000193 formoterol fumarate Drugs 0.000 claims description 27
- 239000004094 surface-active agent Substances 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 239000007971 pharmaceutical suspension Substances 0.000 claims description 15
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 13
- 230000008961 swelling Effects 0.000 claims description 13
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 12
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 12
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 12
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000005642 Oleic acid Substances 0.000 claims description 12
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 12
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 12
- 239000008101 lactose Substances 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000013078 crystal Substances 0.000 claims description 7
- 239000003906 humectant Substances 0.000 claims description 7
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 238000005189 flocculation Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229950010030 dl-alanine Drugs 0.000 claims description 3
- 230000016615 flocculation Effects 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 229960001031 glucose Drugs 0.000 claims description 2
- 229960001375 lactose Drugs 0.000 claims description 2
- 239000003708 ampul Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 6
- 229960003767 alanine Drugs 0.000 description 6
- 235000004279 alanine Nutrition 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 5
- 230000003311 flocculating effect Effects 0.000 description 5
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 239000006184 cosolvent Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 229940071648 metered dose inhaler Drugs 0.000 description 4
- 238000004062 sedimentation Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 239000001273 butane Substances 0.000 description 2
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 239000008249 pharmaceutical aerosol Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 2
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 239000004604 Blowing Agent Substances 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- LLCSWKVOHICRDD-UHFFFAOYSA-N buta-1,3-diyne Chemical group C#CC#C LLCSWKVOHICRDD-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002788 crimping Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- UKACHOXRXFQJFN-UHFFFAOYSA-N heptafluoropropane Chemical compound FC(F)C(F)(F)C(F)(F)F UKACHOXRXFQJFN-UHFFFAOYSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000001812 pycnometry Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9612297.3A GB9612297D0 (en) | 1996-06-11 | 1996-06-11 | Medicinal aerosol formulations |
| PCT/US1997/009471 WO1997047286A1 (en) | 1996-06-11 | 1997-06-02 | Medicinal aerosol formulations of formoterol |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO985720D0 NO985720D0 (no) | 1998-12-07 |
| NO985720L NO985720L (no) | 1999-02-11 |
| NO320403B1 true NO320403B1 (no) | 2005-11-28 |
Family
ID=10795182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19985720A NO320403B1 (no) | 1996-06-11 | 1998-12-07 | Farmasoytisksuspensjonsformulering av formoterol egnet for aerosoladministrering, aerosolleverende anordning og fremgangsmate til fremstilling av aerosolformulering |
Country Status (16)
| Country | Link |
|---|---|
| EP (2) | EP0934057B1 (it) |
| JP (1) | JP5000793B2 (it) |
| AR (1) | AR009231A1 (it) |
| AT (1) | ATE275940T1 (it) |
| AU (1) | AU726382B2 (it) |
| CA (1) | CA2257841C (it) |
| DE (1) | DE69730723T2 (it) |
| DK (1) | DK0934057T3 (it) |
| ES (1) | ES2229366T3 (it) |
| GB (1) | GB9612297D0 (it) |
| ID (1) | ID19520A (it) |
| NO (1) | NO320403B1 (it) |
| NZ (1) | NZ333202A (it) |
| PT (1) | PT934057E (it) |
| WO (1) | WO1997047286A1 (it) |
| ZA (1) | ZA974546B (it) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6054488A (en) * | 1996-06-11 | 2000-04-25 | 3M Innovative Properties Company | Medicinal aerosol formulations of formoterol |
| GB9616237D0 (en) | 1996-08-01 | 1996-09-11 | Norton Healthcare Ltd | Aerosol formulations |
| US20010031244A1 (en) | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
| US6423298B2 (en) * | 1998-06-18 | 2002-07-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical formulations for aerosols with two or more active substances |
| US6451285B2 (en) * | 1998-06-19 | 2002-09-17 | Baker Norton Pharmaceuticals, Inc. | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
| DE19847969A1 (de) * | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Lagerfähig flüssige Formulierung mit Formoterol |
| CZ20011362A3 (cs) * | 1998-10-17 | 2001-09-12 | Boehringer Ingelheim Pharma Kg | Skladovatelný koncentrát účinné látky s formoterolem |
| DZ2947A1 (fr) | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Inhalateur à compteur de dose sous pression. |
| IT1303788B1 (it) * | 1998-11-25 | 2001-02-23 | Chiesi Farma Spa | Formulazioni di aerosol medicinali. |
| US6290930B1 (en) | 1998-12-18 | 2001-09-18 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide |
| US6004537A (en) * | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
| IT1313553B1 (it) | 1999-07-23 | 2002-09-09 | Chiesi Farma Spa | Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione. |
| IT1317846B1 (it) | 2000-02-22 | 2003-07-15 | Chiesi Farma Spa | Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva. |
| JP5392880B2 (ja) | 2000-05-22 | 2014-01-22 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | 加圧式定量吸入器のための安定な製薬学的溶液製剤 |
| SE0004750D0 (sv) * | 2000-12-19 | 2000-12-19 | Astrazeneca Ab | Novel formulation |
| US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| DE60103527T2 (de) | 2001-07-02 | 2005-06-16 | Chiesi Farmaceutici S.P.A. | Optimierte Tobramycin-Formulierung zur Aerosolbildung |
| TWI324934B (en) * | 2001-08-28 | 2010-05-21 | Schering Corp | Pharmaceutical compositions for the treatment of asthma |
| GB0207899D0 (en) * | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and cielesonide aerosol formulations |
| GB0207906D0 (en) | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and mometasone aerosol formulations |
| WO2004020289A1 (en) | 2002-08-27 | 2004-03-11 | Schering Corporation | Process for producing metered dose inhaler formulations |
| EP1635845A1 (en) * | 2003-06-13 | 2006-03-22 | ALTANA Pharma AG | Formoterol and ciclesonide combination |
| TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| EP1925293A3 (en) * | 2003-10-20 | 2010-01-13 | Schering Corporation | Pharmaceutical aerosol compositions |
| CA2542530A1 (en) * | 2003-10-20 | 2005-05-12 | Schering Corporation | Pharmaceutical aerosol compositions |
| EP1595531A1 (en) | 2004-05-13 | 2005-11-16 | CHIESI FARMACEUTICI S.p.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
| AU2007313077B2 (en) * | 2006-10-17 | 2011-06-02 | Neothetics, Inc. | Methods, compositions, and formulations for the treatment of thyroid eye disease |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| AU2010253770B9 (en) | 2009-05-29 | 2015-02-12 | Pearl Therapeutics, Inc. | Compositions for respiratory delivery of active agents and associated methods and systems |
| RS53514B1 (sr) * | 2009-10-02 | 2015-02-27 | Chiesi Farmaceutici S.P.A. | Farmaceutske aerosolne formulacije od formoterola i beklometazon dipropionata |
| US20140275517A1 (en) | 2013-03-15 | 2014-09-18 | Pearl Therapeutics, Inc. | Methods and systems for conditioning of particulate crystalline materials |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2050905A1 (en) * | 1989-02-23 | 1990-08-24 | George R. Felt | Therapeutic aerosol formulations |
| IE67185B1 (en) * | 1990-02-02 | 1996-03-06 | Fisons Plc | Propellant compositions |
| GB9024365D0 (en) * | 1990-11-09 | 1991-01-02 | Glaxo Group Ltd | Medicaments |
| EP0504112A3 (en) * | 1991-03-14 | 1993-04-21 | Ciba-Geigy Ag | Pharmaceutical aerosol formulations |
| DK1277467T3 (da) * | 1991-06-10 | 2007-01-15 | Schering Corp | Formuleringer af ikke-chlorfluorcarbonaerosoler |
| ES2200771T3 (es) * | 1991-06-10 | 2004-03-16 | Schering Corporation | Formulaciones en aerosol no clorofluorocarbonadas. |
| ATE128350T1 (de) * | 1991-12-12 | 1995-10-15 | Glaxo Group Ltd | Pharmazeutische aerosolformulierung. |
| IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
| DK0617610T3 (da) * | 1991-12-18 | 1997-10-06 | Minnesota Mining & Mfg | Suspensionsaerosolformuleringer. |
| GB9207400D0 (en) * | 1992-04-02 | 1992-05-13 | Smithkline Beecham Plc | Novel use |
| US5354934A (en) * | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| GB9425160D0 (en) * | 1994-12-10 | 1995-02-08 | Glaxo Group Ltd | Medicaments |
| GB9426252D0 (en) * | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
-
1996
- 1996-06-11 GB GBGB9612297.3A patent/GB9612297D0/en active Pending
-
1997
- 1997-05-23 ZA ZA974546A patent/ZA974546B/xx unknown
- 1997-06-02 PT PT97929756T patent/PT934057E/pt unknown
- 1997-06-02 EP EP97929756A patent/EP0934057B1/en not_active Expired - Lifetime
- 1997-06-02 NZ NZ333202A patent/NZ333202A/en not_active IP Right Cessation
- 1997-06-02 CA CA002257841A patent/CA2257841C/en not_active Expired - Lifetime
- 1997-06-02 AU AU33739/97A patent/AU726382B2/en not_active Expired
- 1997-06-02 EP EP03014565A patent/EP1400239A1/en not_active Withdrawn
- 1997-06-02 DE DE69730723T patent/DE69730723T2/de not_active Expired - Lifetime
- 1997-06-02 AT AT97929756T patent/ATE275940T1/de not_active IP Right Cessation
- 1997-06-02 WO PCT/US1997/009471 patent/WO1997047286A1/en not_active Ceased
- 1997-06-02 DK DK97929756T patent/DK0934057T3/da active
- 1997-06-02 ES ES97929756T patent/ES2229366T3/es not_active Expired - Lifetime
- 1997-06-02 JP JP50165698A patent/JP5000793B2/ja not_active Expired - Lifetime
- 1997-06-04 AR ARP970102437A patent/AR009231A1/es unknown
- 1997-06-09 ID IDP971970A patent/ID19520A/id unknown
-
1998
- 1998-12-07 NO NO19985720A patent/NO320403B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5000793B2 (ja) | 2012-08-15 |
| DE69730723T2 (de) | 2005-10-06 |
| DE69730723D1 (de) | 2004-10-21 |
| WO1997047286A1 (en) | 1997-12-18 |
| EP0934057B1 (en) | 2004-09-15 |
| ZA974546B (en) | 1998-11-23 |
| NZ333202A (en) | 2000-06-23 |
| EP0934057A1 (en) | 1999-08-11 |
| PT934057E (pt) | 2004-12-31 |
| NO985720D0 (no) | 1998-12-07 |
| GB9612297D0 (en) | 1996-08-14 |
| JP2000513340A (ja) | 2000-10-10 |
| AU3373997A (en) | 1998-01-07 |
| EP1400239A1 (en) | 2004-03-24 |
| ES2229366T3 (es) | 2005-04-16 |
| CA2257841C (en) | 2008-05-20 |
| ATE275940T1 (de) | 2004-10-15 |
| AR009231A1 (es) | 2000-04-12 |
| DK0934057T3 (da) | 2005-01-24 |
| ID19520A (id) | 1998-07-16 |
| CA2257841A1 (en) | 1997-12-18 |
| AU726382B2 (en) | 2000-11-02 |
| NO985720L (no) | 1999-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2257841C (en) | Medicinal aerosol formulations of formoterol | |
| US6054488A (en) | Medicinal aerosol formulations of formoterol | |
| AU658854B2 (en) | Aerosol formulation comprising beclomethasone 17,21 dipropionate | |
| US5776432A (en) | Beclomethasone solution aerosol formulations | |
| US5190029A (en) | Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content | |
| JP4672143B2 (ja) | 医薬用エーロゾル製剤 | |
| AU732985B2 (en) | Medicinal aerosol formulations comprising budesonide | |
| US6039932A (en) | Medicinal inhalation aerosol formulations containing budesonide | |
| CZ194797A3 (en) | Pharmaceutical aerosol preparation, process of its preparation and use | |
| EP1100465A1 (de) | Medizinische aerosolformulierungen | |
| KR20010053025A (ko) | 가압 정량 흡입기 및 제약학적 분무 제제형 | |
| WO1993011747A1 (en) | Suspension aerosol formulations | |
| CZ20032915A3 (en) | Medical aerosol formulations | |
| EP1492500A1 (en) | Formoterol and ciclesonide aerosol formulations | |
| CA2263905C (en) | Chlorofluorocarbon-free mometasone furoate aerosol formulations | |
| CN109789131A (zh) | 药物组合物 | |
| WO1993011745A1 (en) | Medicaments | |
| Patel et al. | Formation of fluorinated nonionic surfactant microemulsions in hydrofluorocarbon 134a (HFC 134a) | |
| DK2488158T3 (en) | IMPROVED medicinal aerosol | |
| US5753208A (en) | Antiasthmatic aerosol preparation of sodium cromoglycate | |
| AU645366B2 (en) | Aerosol composition and a process preparing same | |
| AU2013201071A1 (en) | Improved medicinal aerosol formulations |